Baystreet.ca News Commentary – In the United States, federal budget cuts threaten to slow the nation’s progress in the fight against cancer, but the private sector appears ...

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

FDA approval of IBTROZI (taletrectinib) transformed Nuvation Bio into a commercial-stage company, driving $4.8 million in GAAP revenue, well above GAAP revenue estimates. Earnings per share (GAAP) was ...

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 ...

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the penny stocks that will skyrocket. On June 24, the company confirmed the addition of its Taletrectinib (IBTROZI) treatment as a Preferred Agent in the ...

Nuvation Bio Inc. (NYSE: NUVB) is one of the penny stocks that will skyrocket. On June 24, the company confirmed the addition of its Taletrectinib (IBTROZI) treatment as a Preferred Agent in the ...